Cargando…

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease

INTRODUCTION: Inhaled β-agonists have been foundational medications for maintenance COPD management for decades. Through activation of cyclic adenosine monophosphate pathways, these agents relax airway smooth muscle and improve expiratory airflow by relieving bronchospasm and alleviating air trappin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burkes, Robert M, Panos, Ralph J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751789/ https://www.ncbi.nlm.nih.gov/pubmed/33364854 http://dx.doi.org/10.2147/JEP.S259328

Ejemplares similares

Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
por: Rossi, Andrea, et al.
Publicado: (2008)

The safety of long-acting β(2)-agonists in the treatment of stable chronic obstructive pulmonary disease
por: Decramer, Marc L, et al.
Publicado: (2013)

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents
por: Tashkin, Donald P, et al.
Publicado: (2010)

The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
por: Zhou, Ji’an, et al.
Publicado: (2021)

Management of Asthma and Chronic Obstructive Pulmonary Disease with Combination Inhaled Corticosteroids and Long-Acting β-Agonists: A Review of Comparative Effectiveness Research
por: Mapel, Douglas W., et al.
Publicado: (2014)

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
por: Donohue, James F, et al.
Publicado: (2017)

Long acting β(2 )agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials
por: Husereau, Don, et al.
Publicado: (2004)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
por: Muraki, Masato, et al.
Publicado: (2021)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
por: Liao, Pei-An, et al.
Publicado: (2023)

Efficacy and safety of the long-acting β(2)-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease
por: Ichinose, Masakazu, et al.
Publicado: (2015)

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
por: DiSantostefano, Rachael L, et al.
Publicado: (2014)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Therapeutic preferences and factors determining the use of inhaled corticosteroids with long-acting β(2)-agonists in patients with asthma and chronic obstructive pulmonary disease
por: Olszanecka-Glinianowicz, Magdalena, et al.
Publicado: (2020)

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis
por: Zeng, Shasha, et al.
Publicado: (2022)

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease
por: Donohue, James F, et al.
Publicado: (2011)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long‐Acting β (2)‐Agonists and Inhaled Corticosteroids: The OUTPUL Study
por: Ferroni, Eliana, et al.
Publicado: (2016)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
por: Ora, Josuel, et al.
Publicado: (2020)

Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease
por: Panos, Ralph J
Publicado: (2013)

The long-acting β(2)-adrenoceptor agonist olodaterol attenuates pulmonary inflammation
por: Wex, Eva, et al.
Publicado: (2015)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2023)

The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease
por: Kliber, Agnes, et al.
Publicado: (2010)

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
por: Requena, Gema, et al.
Publicado: (2023)

A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β-agonists in health insurance claims data
por: Dore, David D, et al.
Publicado: (2014)

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2022)

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
por: Beier, Jutta, et al.
Publicado: (2011)

Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists
por: Rebordosa, Cristina, et al.
Publicado: (2022)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β(2)-Agonists
por: Bollu, Vamsi, et al.
Publicado: (2016)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Effect of Inhaled β(2)-Agonist on Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease
por: Amer, Mostafa, et al.
Publicado: (2016)

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
por: Wang, Wenwen, et al.
Publicado: (2023)

Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study
por: Horita, Nobuyuki, et al.
Publicado: (2013)

Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease
por: Wang, Meng-Ting, et al.
Publicado: (2019)

Long acting β(2)-adrenocepter agonists are not associated with atrial arrhythmias after pulmonary resection
por: Yamanashi, Keiji, et al.
Publicado: (2017)

The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review
por: Calzetta, Luigino, et al.
Publicado: (2022)

Impact of Quality Improvement on Care of Chronic Obstructive Pulmonary Disease Patients in an Internal Medicine Resident Clinic
por: Burkes, Robert M., et al.
Publicado: (2018)

Tissue-Specific Ultra-Short Telomeres in Chronic Obstructive Pulmonary Disease
por: Cagsin, Huseyin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_utsnmapisg3oe47mupv26t2c09